{"title": "Improving European healthcare through cell-based interceptive medicine", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2020-09-07", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "- You are here:\nYou are here\n[Home](/en)> Improving European healthcare through cell-based interceptive medicine\nImproving European healthcare through cell-based interceptive medicine\nImproving European healthcare through cell-based interceptive medicine\nImproving European healthcare through cell-based interceptive medicine\nHundreds of innovators, research pioneers, clinicians, industry leaders and policy makers from all around Europe are united by a vision of how to revolutionize healthcare. In two publications \u2013 a perspective article in the journal Nature and the LifeTime Strategic Research Agenda \u2013 they now present a detailed roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual\u2019s lifetime.\nThe\n[LifeTime initiative](https://lifetime-initiative.eu/), including the [Centre for Genomic Regulation (CRG)](https://www.crg.eu) and the [Centro Nacional de An\u00e1lisis Gen\u00f3mico (CNAG-CRG)](https://www.cnag.crg.eu/), based in Barcelona, has developed a strategy to advance personalised treatment for five major disease classes: cancer, neurological-, infectious-, chronic inflammatory- and cardiovascular diseases. The aim is a new age of personalised, cell-based interceptive medicine for Europe with the potential of improved health outcomes and more cost-effective treatment, resulting in profoundly changing a person\u2019s healthcare experience.\nEarlier detection and more effective treatment of diseases\nTo form a functioning, healthy body, our cells follow developmental paths during which they acquire specific roles in tissues and organs. But when they deviate from their healthy course, they accumulate changes leading to disease which remain undetected until symptoms appear. At this point, medical treatment is often invasive, expensive and inefficient. However, now we have the technologies to capture the molecular makeup of individual cells and to detect the emergence of disease or therapy resistance much earlier. Using breakthrough single-cell and imaging technologies in combination with artificial intelligence and personalized disease models will allow us to not only predict disease onset earlier, but also to select the most effective therapies for individual patients. Targeting disease-causing cells to intercept disorders before irreparable damage occurs will substantially improve the outlook for many patients and has the potential of saving billions of Euros of disease-related costs in Europe.\nA detailed roadmap for implementing LifeTime\nThe perspective article \u201cLifeTime and improving European healthcare through cell-based interceptive medicine\u201d and the LifeTime Strategic Research Agenda (SRA) explain how these technologies should be rapidly co-developed, transitioned into clinical settings and applied to the five major disease areas. Close interactions between European infrastructures, research institutions, hospitals and industry will be essential to generate, share and analyse LifeTime\u2019s big medical data across European borders. The initiative\u2019s vision advocates\n[ethically responsible research](https://www.embopress.org/doi/10.15252/embj.2020105725) to benefit citizens all across Europe.\nAccording to Professor Nikolaus Rajewsky, scientific director of the Berlin Institute for Medical System Biology at the Max Delbr\u00fcck Center for Molecular Medicine and coordinator of the LifeTime Initiative, the LifeTime approach is the way into the future:\n\"LifeTime has brought together scientists across fields \u2013 from biologists, to clinicians, data scientists, engineers, mathematicians, and physicists \u2013 to enable a much-improved understanding of molecular mechanisms driving health and disease. Cell-based medicine will allow doctors to diagnose diseases earlier and intercept disorders before irreparable damage has occurred. LifeTime has a unique value proposition that promises to improve the European patient\u2019s health.\"\nDr. Genevi\u00e8ve Almouzni, Director of research at CNRS, honorary director of the research centre from Institut Curie in Paris and co-coordinator of the LifeTime Initiative believes that the future with LifeTime offers major social and economic impact:\n\u201cBy implementing interceptive, cell-based medicine we will be able to considerably improve treatment across many diseases. Patients all over the world will be able to lead longer, healthier lives. The economic impact could be tremendous with billions of Euros saved from productivity gains simply for cancer, and significantly shortened ICU stays for Covid-19. We hope EU leaders will realize we have to invest in the necessary research now.\"\nMarc A. Marti-Renom, ICREA Research Professor, group leader at the Centro Nacional de An\u00e1lisis Gen\u00f3mico (CNAG-CRG) and the Centre for Genomic Regulation (CRG), and author of the perspective article published, says:\n\u201cLifeTime is the largest effort in EU to bring together complementary disciplines to develop and apply new technologies that can monitor and treat complex diseases over time. There is a momentum that cannot be missed by the EU to organize a strong long-term medical research program.\u201d\nMichela Bertero, Head of the International & Scientific Affairs Office at the Centre for Genomic Regulation (CRG), and also author of the article, believes:\n\u201cThe interdisciplinary approach of LifeTime comes along with a centric-patient vision. Our institute is excited to collaborate with LifeTime in promoting an open dialogue with society and tackling fundamental societal and ethical issues that new technologies often pose\u201d.\nLiterature\n- Rajewsky, N. et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature\n[https://www.nature.com/articles/s41586-020-2715-9](https://www.nature.com/articles/s41586-020-2715-9) [LifeTime Strategic Research Agenda](https://lifetime-initiative.eu/lifetime-strategic-research-agenda-2/)\n- Torres-Padilla, M. E. et al. Thinking \u2018ethical\u2019 when designing a new biomedical research consortium. EMBO J, doi:\n[https://doi.org/10.15252/embj.2020105725](https://doi.org/10.15252/embj.2020105725)(2020)\nMedia to download\n[Please refer to the media kit on the LifeTime website.](https://lifetime-initiative.eu/media-for-download/)\nContacts\nGloria Lligadas\nHead of Communications & PR\nCentre for Genomic Regulation (CRG)\n+34 608 550 788\n[gloria.lligadas@crg.eu](mailto:gloria.lligadas@crg.eu)\nLifeTime\nValentin Popescu\nCommunication manager for the LifeTime Initiative\nMax Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association (MDC)\n+49 30 9406-2136\n[valentin.popescu@mdc-berlin.de](mailto:valentin.popescu@mdc-berlin.de)\nAbout LifeTime\nThe LifeTime Initiative is a growing community of more than 100 leading European research institutions and hospitals, together with international advisers and over 80 supporting companies. LifeTime includes the preeminent European laboratories developing multi-omic strategies, scientific infrastructures, bioimaging and computational technologies, as well as world-renowned laboratories in the area of personalized disease models, bioethicists and a core group of leading clinician scientists. Many of the involved institutions include or are linked to translational/clinical research facilities and hospitals, ensuring that LifeTime discoveries can be rapidly translated into clinical practice.\nMejora de la asistencia m\u00e9dica europea mediante la medicina interceptiva basada en c\u00e9lulas\nCentenares de innovadores, pioneros en investigaci\u00f3n, m\u00e9dicos, l\u00edderes de la industria y legisladores de toda Europa unidos por la visi\u00f3n de c\u00f3mo revolucionar la asistencia m\u00e9dica. En dos publicaciones \u2013 un art\u00edculo de perspectiva en la revista Nature y la Agenda de Investigaci\u00f3n Estrat\u00e9gica de LifeTime\u2013 ahora presentan un mapa de ruta detallado de c\u00f3mo potenciar los \u00faltimos avances cient\u00edficos y las tecnolog\u00edas a lo largo de la pr\u00f3xima d\u00e9cada, para seguir la pista, comprender y tratar las c\u00e9lulas humanas a lo largo de la toda la vida de una persona.\nLa\n[iniciativa LifeTime](http://lifetime-initiative.eu/), que incluye al [Centro de Regulaci\u00f3n Gen\u00f3mica (CRG)](http://www.crg.eu) y al [Centro Nacional de An\u00e1lisis Gen\u00f3mico (CNAG-CRG)](http://www.cnag.crg.eu/), en Barcelona, ha desarrollado una estrategia para fomentar el tratamiento personalizado para cinco clases principales de enfermedades: c\u00e1ncer, enfermedades neurol\u00f3gicas, infecciosas, inflamatorias cr\u00f3nicas y cardiovasculares. El objetivo es una nueva etapa de la medicina interceptiva, basada en c\u00e9lulas, y personalizada para Europa con el potencial de obtener resultados de salud mejorados y tratamientos m\u00e1s rentables, lo que deriva en un profundo cambio en la experiencia de la asistencia m\u00e9dica de una persona.\nDetecci\u00f3n temprana y un tratamiento m\u00e1s efectivo de las enfermedades\nPara formar un cuerpo funcional sano, nuestras c\u00e9lulas siguen recorridos evolutivos durante los cuales adquieren roles espec\u00edficos en tejidos y \u00f3rganos. Pero cuando se desv\u00edan de su curso sano, acumulan cambios que provocan enfermedades que permanecen sin detectar hasta que aparecen los s\u00edntomas. En este punto, a menudo el tratamiento m\u00e9dico es invasivo, caro e ineficaz. Sin embargo, ahora disponemos de las tecnolog\u00edas para capturar la composici\u00f3n molecular de c\u00e9lulas individuales y detectar mucho antes la aparici\u00f3n de la resistencia a enfermedades o terapias. Mediante el uso de tecnolog\u00edas innovadoras de c\u00e9lula \u00fanica y de imagen en combinaci\u00f3n con la inteligencia artificial y modelos de enfermedad personalizados, no solo podremos predecir antes la aparici\u00f3n de la enfermedad, sino tambi\u00e9n seleccionar las terapias individuales m\u00e1s efectivas para los pacientes. La localizaci\u00f3n de las c\u00e9lulas que provocan la enfermedad para interceptar trastornos antes de que se produzcan da\u00f1os irreparables mejorar\u00e1 considerablemente la perspectiva de muchos pacientes, adem\u00e1s de tener el potencial de ahorrar miles de millones de euros de costes relacionados con enfermedades en Europa.\nUn mapa de ruta detallado para implementar LifeTime\nEl art\u00edculo de perspectiva \u00abThe LifeTime initiative and the future of cell-based interceptive medicine in Europe\u00bb y la Agenda de Investigaci\u00f3n Estrat\u00e9gica de LifeTime (SRA, en sus siglas en ingl\u00e9s) explican c\u00f3mo estas tecnolog\u00edas deber\u00edan co-desarrollarse r\u00e1pidamente, traducirse en la pr\u00e1ctica cl\u00ednica y aplicarse a las cinco \u00e1reas principales de enfermedades. Las estrechas interacciones entre las infraestructuras europeas, los institutos de investigaci\u00f3n, hospitales y la industria ser\u00e1n decisivas para generar, compartir y analizar los macrodatos m\u00e9dicos de LifeTime a lo ancho y largo de Europa. La visi\u00f3n de la iniciativa promueve una\n[investigaci\u00f3n \u00e9ticamente responsable](http://www.embopress.org/doi/10.15252/embj.2020105725) que beneficie a todos los ciudadanos europeos.\nSeg\u00fan el Profesor Nikolaus Rajewsky, director cient\u00edfico del Berlin Institute for Medical System Biology en el Max Delbr\u00fcck Center for Molecular Medicine y coordinador de la Iniciativa LifeTime, el enfoque de LifeTime es el camino hacia el futuro:\n\u00abLifeTime ha unido a cient\u00edficos de todos los \u00e1mbitos, desde bi\u00f3logos hasta m\u00e9dicos, cient\u00edficos de datos, ingenieros, matem\u00e1ticos y f\u00edsicos, para lograr una comprensi\u00f3n mucho mejor de los mecanismos moleculares que controlan la salud y las enfermedades. La medicina basada en c\u00e9lulas permitir\u00e1 a los m\u00e9dicos diagnosticar enfermedades con antelaci\u00f3n e interceptar trastornos antes de que se produzcan da\u00f1os irreparables. LifeTime tiene una propuesta de valor \u00fanica que promete mejorar la salud de los pacientes europeos.\"\nLa Dra. Genevi\u00e8ve Almouzni, directora de investigaci\u00f3n en el CNRS, directora honor\u00edfica del centro de investigaci\u00f3n del Instituto Curie en Par\u00eds y coordinadora adjunta de la iniciativa LifeTime, cree que el futuro con LifeTime ofrece un mayor impacto social y econ\u00f3mico:\n\u00abAl implementar la medicina interceptiva basada en c\u00e9lulas podremos mejorar considerablemente el tratamiento de muchas enfermedades. Los pacientes de todo el mundo podr\u00e1n vivir m\u00e1s a\u00f1os y con m\u00e1s salud. El impacto econ\u00f3mico podr\u00eda ser inmenso con miles de millones de euros de ahorro en ganancias de productividad simplemente para c\u00e1ncer y estancias mucho m\u00e1s cortas en la UCI a causa de la Covid-19. Esperamos que los l\u00edderes de la UE entiendan que tenemos que invertir en la investigaci\u00f3n necesaria ahora\u00bb.\nMarc A. Marti-Renom, Profesor de Investigaci\u00f3n ICREA, jefe de grupo en el Centro Nacional de An\u00e1lisis Gen\u00f3mico (CNAG-CRG) y del Centro de Regulaci\u00f3n Gen\u00f3mica (CRG), y autor del art\u00edculo de perspectiva publicado, dice:\n\u201cLifeTime es el mayor intento en la UE para unir disciplinas complementarias para desarrollar y aplicar nuevas tecnolog\u00edas que pueden monitorizar y tratar enfermedades complejas a lo largo del tiempo. Tenemos un impulso que la UE no puede desperdiciar para organizar un programa de investigaci\u00f3n m\u00e9dica fuerte y a largo plazo.\u201d\nMichela Bertero, directora de la Oficina de Asuntos Internacionales y Cient\u00edficos en el Centro de Regulaci\u00f3n Gen\u00f3mica (CRG), y autora tambi\u00e9n del art\u00edculo, cree que:\n\u201cEl enfoque interdisciplinar de LifeTime se acompa\u00f1a de una visi\u00f3n centrada en el paciente. Nuestro instituto est\u00e1 entusiasmado de colaborar con LifeTime para promover un di\u00e1logo abierto con la sociedad para abordar temas \u00e9ticos y sociales fundamentales que a menudo conllevan las nuevas tecnolog\u00edas\u201d.\nReferencias\n- Rajewsky, N. et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature\n[https://www.nature.com/articles/s41586-020-2715-9](https://www.nature.com/articles/s41586-020-2715-9) [LifeTime Strategic Research Agenda](https://lifetime-initiative.eu/lifetime-strategic-research-agenda-2/)\n- Torres-Padilla, M. E. et al. Thinking \u2018ethical\u2019 when designing a new biomedical research consortium. EMBO J, doi:\n[https://doi.org/10.15252/embj.2020105725](https://doi.org/10.15252/embj.2020105725)(2020)\n[Material gr\u00e1fico para medios](http://lifetime-initiative.eu/media-for-download/)\nContactos\nGloria Lligadas\nHead of Communications & PR\nCentre for Genomic Regulation (CRG)\n+34 608 550 788\n[gloria.lligadas@crg.eu](mailto:gloria.lligadas@crg.eu)\nLifeTime\nValentin Popescu\nCommunication manager for the LifeTime Initiative\nMax Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association (MDC)\n+49 30 9406-2136\n[valentin.popescu@mdc-berlin.de](mailto:valentin.popescu@mdc-berlin.de)\nAcerca de LifeTime\nLa Iniciativa LifeTime es una comunidad en crecimiento de m\u00e1s de 100 institutos de investigaci\u00f3n y hospitales l\u00edderes europeos, junto con asesores internacionales y m\u00e1s de 80 empresas que la apoyan. LifeTime incluye los laboratorios europeos sobresalientes que desarrollan estrategias multi\u00f3micas, infraestructuras cient\u00edficas, tecnolog\u00edas de bioim\u00e1genes y computacionales, as\u00ed como laboratorios de renombre mundial en el \u00e1mbito de los modelos de enfermedad personalizados, especialistas en bio\u00e9tica y un grupo central de investigadores cl\u00ednicos l\u00edderes. Muchos de los institutos implicados incluyen o est\u00e1n vinculados a centros de investigaci\u00f3n y hospitales translacionales/cl\u00ednicos garantizando que los hallazgos de LifeTime puedan trasladarse r\u00e1pidamente a la pr\u00e1ctica cl\u00ednica.\nMillora de l\u2019assist\u00e8ncia m\u00e8dica europea a trav\u00e9s de la medicina interceptiva basada en c\u00e8l\u00b7lules\nCentenars d\u2019innovadors, pioners de la recerca, metges, l\u00edders de la ind\u00fastria i legisladors de tota Europa units per la visi\u00f3 de com revolucionar l\u2019assist\u00e8ncia m\u00e8dica. En dues publicacions \u2013un article de perspectiva a la revista Nature y l\u2019Agenda de Recerca Estrat\u00e8gica LifeTime- es presenta ara un mapa de ruta detallat de com potenciar els darrers aven\u00e7os cient\u00edfics i les tecnologies al llarg de la propera d\u00e8cada, per seguir la pista, comprendre i tractar les c\u00e8l\u00b7lules humanes al llarg de tota la vida d\u2019una persona.\nLa\n[iniciativa LifeTime](http://lifetime-initiative.eu/), que inclou el [Centre de Regulaci\u00f3 Gen\u00f2mica (CRG)](http://www.crg.eu) i el [Centre Nacional d\u2019An\u00e0lisi Gen\u00f2mica (CNAG-CRG)](http://www.cnag.crg.eu/), a Barcelona, ha desenvolupat una estrat\u00e8gia per a fomentar el tractament personalitzat de cinc classes principals de malalties: c\u00e0ncer, malalties neurol\u00f2giques, infeccioses, inflamat\u00f2ries cr\u00f2niques i cardiovasculars. L\u2019objectiu \u00e9s una nova etapa de la medicina interceptiva, basada en c\u00e8l\u00b7lules, i personalitzada per a Europa amb el potencial d\u2019obtenir resultats de salut millorats i tractaments m\u00e9s rentables, fet que deriva en un canvi profund en l\u2019experi\u00e8ncia de l\u2019assist\u00e8ncia m\u00e8dica d\u2019una persona.\nDetecci\u00f3 primerenca i un tractament m\u00e9s efectiu de les malalties\nPer a formar un cos funcional sa, les nostres c\u00e8l\u00b7lules segueixen recorreguts evolutius durant els quals adquireixen rols espec\u00edfics en teixits i \u00f2rgans. Per\u00f2 quan es desvien del seu curs sa, acumulen canvis que provoquen malalties que romanen sense detectar fins que apareixen els s\u00edmptomes. En aquest punt, sovint el tractament m\u00e8dic \u00e9s invasiu, car i inefica\u00e7. Tanmateix, ara disposem de les tecnologies per capturar la composici\u00f3 molecular de c\u00e8l\u00b7lules individuals i detectar molt abans l\u2019aparici\u00f3 de la resist\u00e8ncia a malalties o ter\u00e0pies. Mitjan\u00e7ant l\u2019\u00fas de tecnologies innovadores de c\u00e8l\u00b7lula \u00fanica i d\u2019imatge en combinaci\u00f3 amb la intel\u00b7lig\u00e8ncia artificial i models de malalties personalitzats, no nom\u00e9s podrem predir abans l\u2019aparici\u00f3 de la malaltia, sin\u00f3 tamb\u00e9 seleccionar les ter\u00e0pies individuals m\u00e9s efectives per als pacients. La localitzaci\u00f3 de les c\u00e8l\u00b7lules que provoquen la malaltia per a interceptar els trastorns abans que es produeixin danys irreparables millorar\u00e0 considerablement la perspectiva de molts pacients, a m\u00e9s de tenir el potencial d\u2019estalviar milers de milions d\u2019euros de despeses relacionades amb malalties a Europa.\nUn mapa de ruta detallat per a implementar LifeTime\nL\u2019article de perspectiva \u00abThe LifeTime initiative and the future of cell-based interceptive medicine in Europe\u00bb i l\u2019Agenda de Recerca Estrat\u00e8gica de LifeTime (SRA, en les seves sigles en angl\u00e8s) expliquen com aquestes tecnologies haurien de co-desenvolupar-se r\u00e0pidament, traduir-se en la pr\u00e0ctica cl\u00ednica i aplicar-se a les cinc \u00e0rees principals de malalties. Les estretes interaccions entre les infraestructures europees, els instituts de recerca, hospitals i la ind\u00fastria seran decisives per a generar, compartir i analitzar les dades m\u00e8diques massives de LifeTime a tota Europa. La visi\u00f3 de la iniciativa promou una\n[recerca \u00e8ticament responsable](http://www.embopress.org/doi/10.15252/embj.2020105725) que benefici\u00ef a tots els ciutadans europeus.\nSegons el Professor Nikolaus Rajewsky, director cient\u00edfic del Berlin Institute for Medical System Biology al Max Delbr\u00fcck Center for Molecular Medicine i coordinador de la iniciativa LifeTime, l\u2019enfocament de LifeTime\u00e9s el cam\u00ed cap al futur:\n\u00abLifeTime ha unit a cient\u00edfics de tots els \u00e0mbits, des de bi\u00f2legs fins a metges, cient\u00edfics de dades, enginyers, matem\u00e0tics i f\u00edsics, per assolir una comprensi\u00f3 molt millor dels mecanismes moleculars que controlen la salut i les malalties. La medicina basada en c\u00e8l\u00b7lules permetr\u00e0 als metges diagnosticar malalties amb antelaci\u00f3 i interceptar trastorns abans que es produeixin danys irreparables. LifeTime t\u00e9 una proposta de valor \u00fanica que promet millorar la salut dels pacients europeus\u00bb.\nLa Dra. Genevi\u00e8ve Almouzni, directora de recerca al CNRS, directora honor\u00edfica del centre de recerca del Institut Curie a Par\u00eds i coordinadora adjunta de la iniciativa LifeTime, creu que el futur amb LifeTime ofereix un impacte social i econ\u00f2mic m\u00e9s gran:\n\u00abA l\u2019implementar la medicina interceptiva basada en c\u00e8l\u00b7lules podrem millorar considerablement el tractament de moltes malalties. Els pacients de tots el m\u00f3n podran viure m\u00e9s anys i amb m\u00e9s salut. L\u2019impacte econ\u00f2mic podria ser immens amb milers de milions d\u2019euros d\u2019estalvi en guanys de productivitat simplement per al c\u00e0ncer i estades molt m\u00e9s curtes a la UCI a causa de la Covid-19. Esperem que els l\u00edders de la UE entenguin que hem d\u2019invertir en la recerca necess\u00e0ria ara\u00bb.\nMarc A. Marti-Renom, Professor d\u2019Investigaci\u00f3 ICREA, cap de grup al Centre Nacional d\u2019An\u00e0lisi Gen\u00f2mica (CNAG-CRG) i del Centre de Regulaci\u00f3 Gen\u00f2mica (CRG), i autor de l\u2019article de perspectiva publicat, diu:\n\u201cLifeTime \u00e9s l\u2019intent m\u00e9s important a la UE per unir disciplines complement\u00e0ries per desenvolupar i aplicar noves tecnologies que puguin monitoritzar i tractar malalties complexes al llarg del temps. Tenim un impuls que la UE no pot desaprofitar per a organitzar un programa de recerca m\u00e8dica fort i a llarg termini\u00bb.\nMichela Bertero, directora de l\u2019Oficina d\u2019Afers Internacionals i Cient\u00edfics al Centre de Regulaci\u00f3 Gen\u00f2mica (CRG), i autora tamb\u00e9 de l\u2019article, creu que:\n\u00abL\u2019enfocament interdisciplinari de Lifetime s\u2019acompanya d\u2019una visi\u00f3 centrada en el pacient. El nostre institut est\u00e0 entusiasmat de col\u00b7laborar amb LifeTime per promoure un di\u00e0leg obert amb la societat per abordar temes \u00e8tics i socials fonamentals que sovint comporten les noves tecnologies\u00bb.\nRefer\u00e8ncies\n- Rajewsky, N. et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature\n[https://www.nature.com/articles/s41586-020-2715-9](https://www.nature.com/articles/s41586-020-2715-9) [LifeTime Strategic Research Agenda](https://lifetime-initiative.eu/lifetime-strategic-research-agenda-2/)\n- Torres-Padilla, M. E. et al. Thinking \u2018ethical\u2019 when designing a new biomedical research consortium. EMBO J, doi:\n[https://doi.org/10.15252/embj.2020105725](https://doi.org/10.15252/embj.2020105725)(2020)\n[Material gr\u00e0fic per a mitjans](http://lifetime-initiative.eu/media-for-download/)\nContactes\nGloria Lligadas\nHead of Communications & PR\nCentre for Genomic Regulation (CRG)\n+34 608 550 788\n[gloria.lligadas@crg.eu](mailto:gloria.lligadas@crg.eu)\nLifeTime\nValentin Popescu\nCommunication manager for the LifeTime Initiative\nMax Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association (MDC)\n+49 30 9406-2136\n[valentin.popescu@mdc-berlin.de](mailto:valentin.popescu@mdc-berlin.de)\nSobre LifeTime\nLa iniciativa LifeTime \u00e9s una comunitat en creixement de m\u00e9s de 100 instituts de recerca i hospitals l\u00edders a Europa, juntament amb assessors internacionals i m\u00e9s de 80 empreses que li donen suport. LifeTime inclou laboratoris europeus excel\u00b7lents que desenvolupen estrat\u00e8gies multi\u00f2miques, infraestructures cient\u00edfiques, tecnologies de bioimatges i computacionals, aix\u00ed com laboratoris de renom mundial en l\u2019\u00e0mbit dels models de malaltia personalitzats, especialistes en bio\u00e8tica i un grup central d\u2019investigadors cl\u00ednics l\u00edders. Molts dels instituts implicats inclouen o estan vinculats a centres de recerca i hospitals traslacionals/cl\u00ednics garantint que les troballes de LifeTime puguin traslladar-se r\u00e0pidament a la pr\u00e0ctica cl\u00ednica.", "language": null, "image": null, "pagetype": null, "links": ["https://es-es.facebook.com/centreforgenomicregulation", "https://twitter.com/CRGenomica", "https://www.youtube.com/user/CRGchannel", "/en", "/en/content/about-us/general-information", "/en/content/about-us/general-information", "/en/content/about-us/institutional-agreements-old", "/en/content/about-us/strategy-and-funding", "/en/content/about-us/contact", "https://tbdo.crg.eu", "/en/content/about-us/management", "https://alumni.crg.eu", "/en/content/about-us/open-science", "/en/content/about-us/science-and-society", "/en/content/about-us/equality-diversity-and-inclusion-edi", "/en/content/about-us/donate", "/en/content/research/faculty-members", "/en/content/research/faculty-members", "/en/content/research/staff-scientists", "https://alumni.crg.eu/faculty-alumni", "/en/research-0", "/en/content/research/scientific-publications", "/en/content/research/projects", "/en/content/research/covid-19-projects", "/en/content/research/orfeu-programme/orfeu-programme", "/en/content/scientific-services/core-technologies", "/en/content/scientific-services/core-technologies", "/en/content/scientific-services/software", "https://ega-archive.org", "/en/content/scientific-services/prbb-ufablab", "/en/content/careers/hr-excellence-research", "/en/content/careers/hr-excellence-research", "/en/content/jobs/jobs", "/en/content/jobs/junior-group-leader-recruitment", "/en/content/careers/relocation-barcelona", "/en/content/careers/career-development", "/en/content/careers/working-crg", "/en/content/training", "/en/content/training/undergraduates-and-masters", "/en/content/training/phd-students", "/en/content/training/postdoctoral-researchers", "/en/content/training/courses-0", "https://tbdo.crg.eu", "/en/events", "/en/events", "/en/content/events/crg-scientific-sessions", "/en/content/events/prbb-crg-sessions", "https://www.prbb.org/agenda-prbb", "/en/content/events/outreach-activities", "/en/content/training/courses", "/en/news", "/en/news", "/en/medias", "/en/content/about-us-administration-communications-pr/institutional-publications", "/en", "http://twitter.com/share", "https://www.crg.eu/sites/default/files/single-cell-2-c-felix-petermann-mdclifetime-1024x683.jpg", "#s1", "#s2", "https://lifetime-initiative.eu/", "https://www.crg.eu", "https://www.cnag.crg.eu/", "https://www.embopress.org/doi/10.15252/embj.2020105725", "https://www.nature.com/articles/s41586-020-2715-9", "https://lifetime-initiative.eu/lifetime-strategic-research-agenda-2/", "https://doi.org/10.15252/embj.2020105725", "https://lifetime-initiative.eu/media-for-download/", "mailto:gloria.lligadas@crg.eu", "mailto:valentin.popescu@mdc-berlin.de", null, "http://lifetime-initiative.eu/", "http://www.crg.eu", "http://www.cnag.crg.eu/", "http://www.embopress.org/doi/10.15252/embj.2020105725", "https://www.nature.com/articles/s41586-020-2715-9", "https://lifetime-initiative.eu/lifetime-strategic-research-agenda-2/", "https://doi.org/10.15252/embj.2020105725", "http://lifetime-initiative.eu/media-for-download/", "mailto:gloria.lligadas@crg.eu", "mailto:valentin.popescu@mdc-berlin.de", null, "http://lifetime-initiative.eu/", "http://www.crg.eu", "http://www.cnag.crg.eu/", "http://www.embopress.org/doi/10.15252/embj.2020105725", "https://www.nature.com/articles/s41586-020-2715-9", "https://lifetime-initiative.eu/lifetime-strategic-research-agenda-2/", "https://doi.org/10.15252/embj.2020105725", "http://lifetime-initiative.eu/media-for-download/", "mailto:gloria.lligadas@crg.eu", "mailto:valentin.popescu@mdc-berlin.de", "/en/news", "/en/medias", "/en/content/about-us-administration-communications-pr/institutional-publications", "mailto:omar.jamshed@crg.eu", "/en/news/2023", "/en/news/2022", "/en/news/2021", "/en/news/2020", "/en/news/2019", "/en/news/2018", "/en/news/2017", "/en/news/2016", "/en/news/2015", "/en/news/2014", "/en/news/2013", "/en/news/2012", "/en/news/2011", "/en/news/2010", "/en/news/2009", "/en/news/2008", "/en/news/2007", "/en/news/2006", "https://www.crg.eu/en/content/legal-notice-privacy-policy", "http://www.crg.eu/en/content/transparency-portal", "https://www.crg.eu/en/content/compliance-communications-channel", "https://www.crg.eu/en/content/crg-webmail-access", "https://www.crg.eu/en/content/eduroam", "https://oim-apps.crg.es/identity/faces/forgotpassword", "https://www.crg.eu/en/content/public-tenders", "https://intranet.crg.eu/", "/directory", "https://www.crg.eu/en/content/about-us/contact", "mailto:Life@CRG", "mailto:Life@CRG", "http://twitter.com/CRGenomica", "http://twitter.com/Silvia_Torello", "http://twitter.com/CRGenomica", "http://twitter.com/GuigoLab", "http://twitter.com/GencodeGenes", "https://t.co/pfCqulfZ49", "http://twitter.com/AgustinLLujan", "http://twitter.com/CRGenomica", "http://twitter.com/the_prbb", "http://twitter.com/NatureComms", "https://t.co/R87uF2A03s"]}